ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of “Moderate Buy” by Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has earned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $29.95.

ACAD has been the subject of several analyst reports. Piper Sandler set a $37.00 price objective on ACADIA Pharmaceuticals in a report on Tuesday. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday. Deutsche Bank Aktiengesellschaft set a $29.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 25th. Needham & Company LLC lifted their price objective on shares of ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Mizuho lifted their price target on ACADIA Pharmaceuticals from $24.00 to $29.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $26.93 on Thursday. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $27.73. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 7.26 and a beta of 0.67. The company’s 50-day simple moving average is $23.59 and its two-hundred day simple moving average is $23.32.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The company had revenue of $278.63 million during the quarter, compared to analyst estimates of $276.52 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. ACADIA Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. Equities analysts expect that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,084 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $96,749.96. Following the sale, the insider owned 25,058 shares in the company, valued at approximately $593,624.02. This represents a 14.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Mark C. Schneyer sold 10,262 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the transaction, the executive vice president owned 53,338 shares of the company’s stock, valued at approximately $1,263,577.22. This represents a 16.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,346 shares of company stock worth $1,010,957 over the last quarter. 26.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Maryland State Retirement & Pension System lifted its position in ACADIA Pharmaceuticals by 1.3% in the second quarter. Maryland State Retirement & Pension System now owns 36,397 shares of the biopharmaceutical company’s stock valued at $785,000 after buying an additional 476 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 11.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 534 shares during the last quarter. Vise Technologies Inc. boosted its position in shares of ACADIA Pharmaceuticals by 4.0% during the 3rd quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 585 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of ACADIA Pharmaceuticals by 0.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock worth $1,964,000 after purchasing an additional 626 shares during the period. Finally, GAMMA Investing LLC increased its holdings in ACADIA Pharmaceuticals by 25.8% in the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 690 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.